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Abstract
Malnutrition predicts poorer clinical outcomes for people with cancer. Older adults with cancer are a complex, growing population
at high risk of weight-losing conditions. A number of malnutrition screening tools exist, however the best screening tool for this
group is unknown. The aim was to systematically review the published evidence regarding markers and measures of nutritional
status in older adults with cancer (age ≥ 70). A systematic search was performed in Ovid Medline, EMBASE, Web of Science,
CINAHL, British Nursing Database and Cochrane CENTRAL; search terms related to malnutrition, cancer, older adults. Titles,
abstracts and papers were screened and quality-appraised. Data evaluating ability of markers of nutritional status to predict patient
outcomes were subjected to meta-analysis or narrative synthesis. Forty-two studies, describing 15 markers were included. Meta-
analysis found decreased food intake was associated with mortality (OR 2.15 [2.03–4.20] p= < 0.00001) in univariate analysis.
Prognostic Nutritional Index (PNI) was associated with overall survival (HR 1.89 [1.03–3.48] p= 0.04). PNI markers (albumin,
total lymphocyte count) could be seen as markers of inflammation rather than nutrition. There a suggested relationship between
very low body mass index (BMI) (<18 kg/m2) and clinical outcomes. No tool was identified as appropriate to screen for
malnutrition, as distinct from inflammatory causes of weight-loss. Risk of cancer-cachexia and sarcopenia in older adults with
cancer limits the tools analysed. Measures of food intake predicted mortality and should be included in clinical enquiry. A screening
tool that distinguishes between malnutrition, cachexia and sarcopenia in older adults with cancer is needed.
Introduction
Older adults with cancer are a growing population who require
complex, multi-layered care to achieve the best possible clinical
outcomes from anticancer treatment [1]. One important, but
often overlooked, aspect of this is nutritional care, which has
been consistently shown to be one of the most predictive and
treatable components of comprehensive oncogeriatric assess-
ment [2].
Malnutrition is caused by a lack of intake or uptake of
nutrition [3, 4], and risk screening is recommended [3] for all
inpatients on admission and outpatients at their first appointment
[5]. A number of malnutrition screening tools exist [6, 7],
although the most appropriate tool for identifying malnutrition in
older adults with cancer is unknown. The varying diagnostic
criteria for malnutrition between screening tools is reflected in
the varying prevalence estimates; for example, the prevalence of
malnutrition in older adults with gastrointestinal cancer varies
between 20 and 52%, depending on the screening tool [8].
Malnutrition screening tools have often been validated
against the subjective global assessment (SGA) [9]. The SGA
was initially validated for use in end-stage renal disease [10],
but has recently been shown to be less reliable than other
nutritional screening tools to predict clinical outcomes in cer-
tain populations [11], such as the NRS-2002 screening tool
which possesses higher specificity and positive predictive value
for post-operative complications [12], and mortality [13] in
hospitalised patients.
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As well as varying markers, the marker thresholds used to
determine nutritional risk differ between tools. For example,
with regard to weight loss, the British Association for Parenteral
and Enteral Nutrition screening tool uses any unintentional
weight loss [14]; the Short Nutritional Assessment Ques-
tionnaire uses >3 kg in 1 month or >6 kg in 6 months [15]; the 3
Minute Nutrition Screening uses >7 kg in an unspecified time
frame [16]; and the European Society for Clinical Nutrition and
Metabolism (ESPEN) screening tool uses >10% in an unspe-
cified time frame [17]. Older adults with cancer exhibit further
complexity given their higher risk of other weight-losing con-
ditions, including sarcopenia and cachexia due to cancer or
other co-morbidities. Cachexia, sarcopenia and malnutrition
have similar clinical presentations and diagnostic criteria
[18, 19]. However, malnutrition has a specific focus on the
‘intake and utilisation’ of nutrition, therefore a screening tool
that can also identify problems with oral intake is required.
To establish which screening tool is most appropriate
to identify malnutrition in older adults with cancer,
markers of malnutrition and their thresholds must be
investigated in relation to their ability to predict poorer
clinical outcomes. The objective of this systematic
review is to identify and synthesise the published evi-
dence about markers of nutritional status in the older
cancer patient. The findings will inform the most
appropriate nutritional screening tool to use in this
population.
Methods
The study protocol was registered with PROSPERO [20], and is
reported in accordance with the Preferred Reporting Items for
Systematic Review and Meta-Analyses (PRISMA) guidelines
[21].
Literature search
Searches were performed by AB and SG between the 6th
and 8th December 2018, from data-based inception to
search date in; Ovid® MEDLINE (Ovid MEDLINE®) and
Epub Ahead of Print, In-Process & Other Non-Indexed
Citations and Daily 1946 to December 5th 2018), EMBASE
via OVID 1980 to 2018 Week 49, Web of Science Core
Collection 1970 to search date, CINAHL Complete
(Cumulative index to Nursing and Allied Health Literature)
via EBSCO 1937 to search date, British Nursing Database
via ProQuest 1994 to search date, and The Cochrane
Database of Systematic Reviews and Cochrane Register of
Controlled Trials (CENTRAL). No limits on publication
date or language were applied.
An initial search combining keywords related to mal-
nutrition, cancer and older adults, using MeSH and text
terms was conducted. On review of the findings, an addi-
tional supplementary search was conducted to include text
terms for individual screening tools that were previously
identified. See online Supplementary information 1 for the
final MEDLINE search strategy. Forward and backward
citation searching of all included studies, and relevant sys-
tematic reviews [22–24], was completed: we examined the
reference lists of included studies and identified articles
citing included studies in Web of Science.
Inclusion and exclusion criteria
Eligible studies had participants aged 70 years or older with
any cancer diagnosis. Studies investigating markers of
nutritional status, used in nutritional screening tools or
objective nutritional indexes [6, 7], against any patient-
related outcome were included. All observational studies
were included, and randomised control trials (RCTs) were
included if study interventions were not nutrition related
(e.g. nutritional interventions). Editorials, case studies, case
reports and conference abstracts without subsequent full
text publication were excluded along with review articles.
Nutritional markers used in screening tools such as disease
state and functional performance were excluded as all par-
ticipants had cancer diagnoses. The relationship between
functional performance and patient outcomes is an estab-
lished individual risk factor for poor patient outcomes [25].
Study selection
All titles and abstracts retrieved by electronic searching
were downloaded to an Endnote X8 library and duplicates
were removed according to a published protocol [26]. The
remaining records were uploaded to the online citation-
screening tool Abstrackr [27]. Studies were initially dual
screened independently (by AB and SG) on the basis of title
and abstract against the eligibility criteria. Where one or
more of the investigators were uncertain whether the article
met the inclusion criteria, the abstract was included and the
full-text article was included for review. All potentially
relevant studies were retrieved and full-texts were reviewed
by AB and SG, with any unresolved disagreements resolved
by consensus or adjudication by a third reviewer (MJ).
Data were extracted by AB, using a custom data extraction
form [20]. Data extraction was piloted, reviewed and modified
before a final extraction from the main papers of the included
studies, with use of supplementary materials as necessary.
Risk of bias; quality appraisal
Each study was evaluated using the Critical Appraisal Skills
Program checklist [28] items 1–10. The cohort study
checklist was used for all study designs. All included papers
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were evaluated by AB with a random 25% independently
reviewed by GM. See online Supplementary information 2
for quality assessment of studies.
Analysis
A narrative summary with descriptions and comparisons
was completed. Meta-analyses were conducted with suffi-
cient study data (n ≥ 3 studies) with homogeneity of proxy
marker thresholds and patient outcomes. Review Manager
5.3 [29] was used to conduct meta-analyses. The I2 statistic
was used to assess heterogeneity, with a random-effects
model chosen if significant heterogeneity was indicated
[30]. Results were considered significant if confidence
intervals did not include the null value, with corresponding
significance values of p < 0.05.
Results
The search returned 5997 unique articles after deduplica-
tion. Following screenings of titles and abstracts, n= 703
full-text articles were assessed for eligibility, due to the
need to examine demographic tables for age. From this,
42 studies, representing 21,032 participants, published
between 2008 and 2019 were eligible for inclusion. (See
PRISMA flow chart, online supplementary information 3).
Table 1 provides a summary description of the included
studies. There were 14 prospective [31–44], 24 retrospective
cohort studies [45–68], 2 cross-sectional studies [69, 70] and 2
RCTs [71, 72]. Sample sizes ranged from 24 [39] to 12,979
[52]. Studies were globally represented; 24 studies from Asia
[40–43, 46–48, 50, 53–56, 58–66, 68, 70], 14 from Europe
[31–36, 38, 44, 45, 51, 57, 69, 71, 72], and 5 from North
America [37, 39, 49, 52, 67].
Participants (46% men) with a number of cancer primary
sites were represented. Twenty nine studies investigated
single cancer primary sites: 10 gastric [43, 48, 50, 53–
55, 58, 62–64], eight colorectal [49, 51, 52, 59–61, 66, 71],
five non-small cell lung (NSCLC) [45, 47, 56, 65, 67], two
hepatic [40, 46], and one each of breast, bladder, oeso-
phageal and ovarian [31, 57, 68, 72] cancers. The remaining
13 studies investigated mixed cancer diagnoses [32–
39, 41, 42, 44, 69, 70]. All studies were based in secondary
and tertiary healthcare settings; outpatient clinics; che-
motherapy or radiotherapy treatments; or inpatients.
Markers of nutritional status
Data extraction revealed 15 markers of nutritional status:
four ‘objective indexes’ (Prognostic Nutritional Index
[PNI], Controlling Nutritional Status Score [CONUT],
Nutritional Risk Index [NRI], Geriatric Nutritional Risk
Index [GNRI] [36, 43, 46, 48, 50, 53–66, 68]; see Table 2;
six anthropometric markers (body mass index [BMI],
weight loss, mid-arm and calf circumference
[33, 35, 37, 38, 40, 41, 44–48, 50, 52–57, 61, 67, 69–72];
two measures of muscle strength (hand-grip, lean skeletal
muscle mass by computed tomography [CT] [39, 51, 70],
three biochemical markers (haemoglobin, albumin and C-
reactive protein [31, 32, 34, 37, 38, 40, 41, 45, 46, 49,
50, 58, 60, 61, 67, 69–72]; and food and fluid measures
[33, 35, 42]. Patient outcomes included survival, mortal-
ity, chemotherapy complications (including dose-
reductions and toxicities), post-operative complications
(including post-operative delirium [POD], functional
decline and treatment modifications) and caregiver
burden.
Dietary intake
Two studies [33, 35] investigated five markers of food intake:
declining [33] or decreasing food intake, number of daily full
meals, protein-rich food intake, fruit and vegetable intake and
mode of feeding [35]. Only one study [33] performed mul-
tivariate analysis, observing ‘declining food intake’ to be
associated with overall mortality. All other markers of food
intake reported associations between patient mortality and
declining food intake, regardless of the threshold or marker
used for food intake. Two studies [33, 35] investigated three
comparable scales of declining food intake at univariate level,
allowing meta-analysis of results.
Meta-analysis
A random-effects model was used to combine odds ratios
(ORs) for mortality, with meta-analysis suggesting that
declining food intake is associated with worse increase risk
of mortality in univariate analysis (OR 2.15 [95% CIs
1.61–2.86, p= < 0.0001]), Fig. 1.
Three studies [33, 35, 42] investigated the relationship
between fluid intake and patient outcomes; finding an asso-
ciation in two studies between fluid intake <3 cups/day with
chemotherapy toxicity in univariate analysis [42], and fluid
intake <5 cups/day with overall mortality in univariate ana-
lysis [33]. However, one study observed no relationship
between fluid intake and mortality [35].
Objective indexes
Four objective indexes were identified in the search; PNI,
CONUT, NRI and GNRI, of which 17 studies investigated
PNI [43, 46, 50, 53–66], three GNRI [48, 56, 62], two
CONUT [56, 57] and two investigated NRI [36, 68]. All but
one study [68] investigated the use of objective indexes in
surgical patients.
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Table 1 Characteristics of included studies.
Prospective cohort
studies
Age, years Sample size,
gender
Cancer diagnoses and treatment Malnutrition proxy
marker(s) and units
Patient outcome(s) Follow up Study results [95% CI] Quality score
Aaldricks,
The Netherlands
[31]
≥70 YO
Mean 76 ± 4.8
Range 70–88
n= 55
F= 53
M= 2
Advanced breast cancer.
Chemotherapy.
Alb (</≥ 35 g/l)
Hb (</≥7.5 mmol/l)
Overall mortality Median 16 ± 13.7
months
No association between
proxy markers and
outcomes.
8.5/10
Risk of selection bias.
≥4 Vs <4 cycles of chemotherapy Median 11 months
Range 0–57.
Aaldricks,
The Netherlands
[32]
≥70 YO
Mean 77
n= 44
F= 25
M= 19
Non-Hodgkin’s Lymphoma;
diffuse large-β cell lymphoma
and follicular lymphoma grade
III.
R-CHOP treatment.
Alb (</≥35 g/l).
Hb (6.8 mmol/l).
Completion of chemotherapy.
Mortality.
Median 46 months
(0–101).
Hb associated with early
treatment withdrawal:
multivariate OR 5.41
[0.99–29.8] p= 0.05 and
mortality: HR 4.90
[1.76–13.7], p= 0.0002.
9.5/10
Aaldricks,
The Netherlands
[33]
≥70 YO
Median 75
Range 70–92
n= 494
F= 248
M= 246
Various cancer diagnoses.
Chemotherapy.
Declining food intake
3/12 (severe or
moderate decrease/no
decrease).
Weight loss 3/12.
Feasibility of Chemotherapy
≥4 Vs <4 cycles
Median 17 months
Range 1–101.
Declining food intake OR
2.00 [1.34–3.00], weight
loss 3/12 OR 1.88
[1.26–2.80] associated
with feasibility of
chemotherapy in
univariate analysis.
Declining food intake,
fluid intake ≤5 cups/day
OR 1.76 [1.23–2.52] and
weight loss 6/12 OR 1.38
[1.13–1.69] associated
with mortality in
univariate analysis.
7.0/10
Missing data, unclear
recruitment.
Declining food intake
3/12
Reduced fluid intake
(≤3/3–5/≥5 cups per
day).
Unintentional weight
loss (3 kg in 1/12 or
6 kg in 2/12).
Overall mortality
Baitar,
Belgium [34]
≥70 YO
Median 77
Range 70–95
n= 328
F= 194
M= 134
Breast (38.4%, Colorectal
35.4%, Lung 15.5%, Prostate
6.4%, Ovarian 4.3%).
63.7% new diagnosis, 36.3%
progression or recurrence.
Surgery, chemotherapy,
radiotherapy hormonal therapy.
Hb (</≥11.8/12 g/dl)*
Alb </≥ 35/37 g/l)*
CRP </>5/≥5 mg/l*
Markers also analysed
as continuous
variables
Overall survival Median 60.3 months
[95% CI: 58.6–62.6].
Hb, CRP and Alb
associated with outcome
as dichotomous variables:
Hb HR 1.51 [1.16–1.96].
Alb HR 2.91 [1.44–2.52].
CRP: HR 1.82
[1.37–2.43]. CRP
associated with outcome
as continuous variable:
HR 1.08 [1.06–1.11].
7.5/10
Unclear recruitment
method.
Bourdel-
Marchasson,
France [35]
≥70 YO n= 606
F= 287
M= 319
Lung, Colon, Stomach,
Pancreas, Ovary, Bladder,
CUPSs, Biliary duct, Breast. Life
expectancy ≥12 weeks.
First line chemotherapy.
% Weight loss (none/
<5%, 5–10%, >10%,
missing).
Decreased food intake
3/12 (severe/
moderate/no
decrease).
Actual weight loss 3/
12 (>3 kg, 1–3 kg/
unknown/none).
BMI (<19/>19–<21/
>21–<23/>23 kg/m2)
Daily full meals (1/2/
3 meals).
Protein-rich foods
(low/intermediate/
high).
Fruit & vegetable
intake (<2/≥2
1 year mortality 12 months. In univariate analysis;
reduced food intake 3.12,
weight loss >3 kg or
unknown weight loss,
BMI <23, number of full
meals per day, <2 servings
fruit and vegetables/day,
self-fed with some
difficulty, self-view of
nutritional status, mid-arm
circumference <21 cm,
calf circumference <31 cm
associated with outcome.
5.5/10
n= 33 lost to follow-up,
unclear recruitment
method, risk of bias in
data collection.
A
.
F.
B
u
llo
ck
et
al.
Table 1 (continued)
Prospective cohort
studies
Age, years Sample size,
gender
Cancer diagnoses and treatment Malnutrition proxy
marker(s) and units
Patient outcome(s) Follow up Study results [95% CI] Quality score
servings/day).
Fluid intake (<3/3–5/
>5 cups/day).
Self-view of
nutritional status
(malnourished/
uncertain/no
problem).
Mode of feeding
(assistance/self-fed
with difficulty/no
problem).
MAC (<21/<21–<22/
>22 cm).
Calf circumference
(<31/>31 cm).
Chaufour-André,
France [36]
≥70 YO n= 71
F= 33
M= 38
Digestive, Upper aero- digestive,
Gynaecological, Lung,
Sarcomas, Other. Surgery for
neoplastic pathology.
NRI </> 97.5.
Unintentional weight
loss.
Major complications. Infectious
complications.
Post-operative confusion.
1 month post-
discharge.
Univariate analysis; NRI
associated with post-
operative complications:
OR 0.79 [0.66–0.95]. No
risk factors for
postoperative
complications could be
identified.
6.5/10
Confounding not
accounted for, risk of bias
in recruitment.
Extermann,
USA [37]
≥70 YO
Median 75.5
Range 70–92
n= 518
F= 261
M= 257
Lung, Breast, Non-Hodgkin’s
Lymphoma, Colorectal, Bladder,
other.
Chemotherapy.
BMI > 25 kg/m2.
Hb (g/dl).
Alb (g/dl).
Chemotherapy toxicity; grade 4
haematological or grade 3/4 non-
haematological.
6 months. No association between
proxy markers and
outcome.
6.0/10
Risk of bias recording
proxy markers and
outcomes.
Hoppe,
France [38]
≥70 YO
Median 77.4
Range 70–93
n= 299
F= 122
M= 177
Colon, Pancreatic, Stomach,
Ovarian, Bladder, Prostate,
Lung, Non-Hodgkin’s
lymphoma, CUPs.
First-line chemotherapy.
Weight loss (</≥
10%).
BMI (<19/19–23/
≥23 kg/m2).
Alb (</≥ 35 g/l).
CRP (</≥ 5 mg/l).
Functional decline (ADL score). After first cycle of
chemotherapy
Weight loss associated
with functional decline in
univariate analysis OR
1.86 [no CIs] p= 0.05. No
multivariate analysis
given.
6.5/10
Risk of bias in
recruitment,
inappropriate follow up
time.
Hsu,
Canada [39]
≥70 YO
Median 74.5
Range 70–84
n= 24
F= 7
M= 17
Colorectal or Thoracic cancer.
Chemotherapy.
Hand-grip strength
(bottom 20th
percentile)
Chemotherapy toxicity (grade
3–5).
Dose reduction or delay due to
chemotherapy toxicity.
Discontinuation of chemotherapy
due to toxicity.
Hospitalisation or ED visit due to
chemotherapy.
12 months. p values only, no
association between proxy
marker and outcomes.
2.0/10
Risk of confounding,
unclear recruitment,
inappropriate
conclusions.
Kaibori,
Japan [40]
≥70 YO
Median 77 Mean
78.2 ± 4.8
Range 70–89
n= 71
F= 19
M= 52
Hepatocellular carcinoma.
Hepatic resection.
BMI (</≥ 22 kg/m2).
Alb (</≥4 g/dl).
Post-operative complications
(Clavien-Dindo grade 2–4b)
Length of hospital
stay: 13 days (6–189).
Alb associated with
outcome in univariate
analysis OR 3.66
[1.14–1.76], p= 0.00292.
7.5/10
Risk of selection bias in
recruitment and inclusion
criteria.
Kanesvaran,
Singapore [41]
≥70 YO
Median 77
Range 70–94
n= 249
F= 96
M= 153
All cancer diagnoses; Lung,
Colorectal and Genitourinary
83.5%
BMI (</≥ 30 kg/m2).
Hb (</≥ 12 g/dl).
Alb (</≥35 g/l).
Survival (median months) No info. Hb and albumin
associated with outcome
in univariate analysis.
Multivariate analysis for
Hb not given.
9.0/10
Missing data.
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Table 1 (continued)
Prospective cohort
studies
Age, years Sample size,
gender
Cancer diagnoses and treatment Malnutrition proxy
marker(s) and units
Patient outcome(s) Follow up Study results [95% CI] Quality score
Kim,
South Korea [42]
≥70 YO n= 301
F= 93
M= 208
Colorectal, Lung, Hepato-
biliary, Stomach, Other. Stage
III, IV or unknown.
First-line chemotherapy.
Daily fluid intake (</>
3 cups per day).
≥Grade 3 chemotherapy toxicity Post-chemotherapy
cycles (range 25–75%
2–7 cycles).
Daily fluid intake
associated with outcome.
7.5/10
Recruitment method not
described.
Lu,
China [43]
≥80 YO
Range 80–93
n= 165
F= 30
M= 132
Gastric cancer.
Surgical resection.
PNI </≥45. Systematic complications. Local
complications.
Overall survival. Recurrence free
survival.
Cancer specific survival.
5 years. PNI associated with
recurrence-free survival
9.5/10
Marenco,
Italy [44]
≥70 YO
Median 78
Mean 78 ± 4.8
n= 571
F= 220
M= 351
Colorectal, Gastro-intestinal,
Renal, Bladder, Other.
BMI </≥21 kg/m2 Treatment recommendation
(active vs palliative care).
Survival.
Up to 60 months. BMI associated with
outcome.
6.5/10
High risk of selection
bias.
Retrospective
cohort studies
Age, years Sample size,
gender
Cancer diagnoses and
treatment
Malnutrition proxy
markers
Patient outcomes Follow up Study results [95% CI] Quality score
Fiorelli,
Italy [45]
≥70 YO
Median 75
Mean 74.9 ± 2.6
Range 71–93
n= 117
F= 23
M= 94
Non-small cell lung cancer.
Curative resection.
BMI (≤/> 18.5 kg/m2)
Alb (≥35 g/l)
Weight loss (≥5% 3/12)
Major complications.
Early death (<3/12 post
procedure).
3 months. BMI and albumin associated
with major complications in
univariate analysis.
3.0/10
Risk of selection/recruitment bias,
risk of bias in data collection,
statistics errors.
Harimoto,
Japan [46]
≥70 YO n= 139
F= 41
M= 98
Hepatocellular carcinoma.
Curative hepatic resection.
BMI (kg/m2).
Alb (g/dl).
CRP (mg/dl).
PNI.
Overall survival.
Disease-free survival.
No info. Univariate analysis; CRP
associated with disease-free
survival: HR 1.35 [1.14–1.59].
6.0/10
Risk of bias in data collection.
Kim,
South Korea
[47]
≥70 YO
Median 76
IQR 72–80
n= 122
F= 37
M= 85
Primary non-small cell lung
cancer, ≥ stage IIIB.
Admitted to hospital.
BMI (<18 kg/m2). Survival 6.2 months
(IQR:
2.5–15.3).
BMI associated with outcome. 8.0/10
Missing data. Risk of bias in data
collection.
Kushiyama,
Japan [48]
≥75 YO
Mean 79.6 ± 3.8
n= 348
F= 118
M= 230
Gastric cancer.
Gastrectomy.
BMI (<22 kg/m2).
GNRI (<92).
Post-operative complications
(Clavien-Dindo grade 2–4)
No info. GNRI associated with outcome 9.0/10
Lai,
Canada [49]
≥80YO
Median 83
Range 80–92
n= 60
F= 29
M= 31
Metastatic colorectal cancer.
Chemotherapy.
Hb </≥100 g/l. Chemotherapy dose reduction/
omission or delay >1 week.
Chemotherapy discontinuation
due to toxicity.
Hospitalisation within 30 days of
chemotherapy.
Overall survival.
No info. Hb associated with overall
survival
5.5/10
Recruitment not discussed.
Missing data.
Mikami, Japan
[50]
≥70 YO n= 267
F= 92
M= 175
Primary gastric cancer.
Curative gastrectomy.
BMI (kg/m2).
Hb (g/dl).
PNI </≥ 40.
Overall survival.
Gastric cancer specific survival.
5 years. BMI and PNI associated with
overall survival.
5.5/10
Risk selection bias.
Mosk,
The Netherlands
[51]
≥70 YO
Median 76
IQR: 73–80
n= 251
F= 110
M= 141
Colorectal cancer.
Elective surgery.
Low skeletal muscle
mass (<35.17 females
cm2/m2, <43.19 cm2/m2
males).
Low skeletal muscle
density.
Post-operative delirium. Length of
hospital stay.
Low skeletal muscle mass
associated with outcome.
9.5/10
Neuman,
USA [52]
≥80 YO
Mean 84.4 ± 3.7
n= 12979
F= 7976
M= 5003
Colon cancer.
Surgical resection.
Weight loss. 90 day mortality.
1 year mortality.
1 year. No association between proxy
marker and outcomes.
7.5/10
Risk of bias in data collection.
Sakurai,
Japan [53]
≥75 YO
Mean 79 ± 3.4
n= 147
F= 52
M= 95
Gastric cancer.
Curative gastrectomy.
BMI </≥ 22 kg/m2.
PNI ≤/> 43.8.
Overall survival. 5 years. PNI associated with outcome. 9.0/10
Recruitment method not discussed.
5 year overall survival. 5 years. PNI associated with outcome.
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Table 1 (continued)
Retrospective
cohort studies
Age, years Sample size,
gender
Cancer diagnoses and
treatment
Malnutrition proxy
markers
Patient outcomes Follow up Study results [95% CI] Quality score
Sakurai,
Japan [54]
≥75 YO
Mean 79.2 ± 3.5
n= 175
F= 59
M= 116
Gastric cancer, stage 1.
Gastrectomy.
BMI (<22 kg/m2).
PNI (<45).
7.5/10
Risk of bias handing missing data
and data collection.
Sekiguchi,
Japan [55]
≥85 YO
Median 86
Range 85–93
n= 108
F= 26
M= 82
Gastric cancer.
Endoscopic submucosal
dissection.
PNI </≥ 44.6.
BMI </≥ 24.3 kg/m2
Overall survival. 5 years. PNI associated with outcome. 6.5/10
Risk of bias handing missing data,
data presentation.
Shoji,
Japan [56]
≥75 YO
Median 78
Range 75–91
n= 272
F= 117
M= 155
Primary lung cancer.
Surgical resection.
Preoperative BMI
</≥18.5 kg/m2
Preoperative PNI ≤/> 49.6.
Preoperative CONUT
</≥1.
Preoperative GNRI ≤/>98.
Post-operative comorbidities.
Overall survival.
Median 51
months
Range
0–132.
GNRI associated with outcome. 8.0/10
Risk of bias in data collection.
Stangl-Kremser,
Austria [57]
≥70 YO
Median 82
IQR 75–86
n= 68
F= 13
M= 55
Urothelial carcinoma of the
bladder.
Transurethral resection.
PNI </≥45.2.
CONUT.
BMI kg/m2
Overall survival.
Cancer specific survival.
Median 12.5
months
(IQR:
5.1–23.5).
PNI associated with overall
survival.
3.0/10
Risk of confounding, missing data.
Takama,
Japan [58]
≥75 YO n= 190
F= 60
M= 130
Gastric cancer.
Gastrectomy.
Alb </≥3.5 g/dl.
PNI </≥40.
Complications (Clavien-Dindo
Grade ≥2).
Mean 46
months.
PNI p= 0.005 [no CI] and Alb p
= 0.019 [no CI] associated with
complications in ages ≥85.
4.0/10
Recruitment method not discussed.
Data presentation.
Tei,
Japan [59]
≥71 YO n= 129
F= 54
M= 75
Colorectal cancer.
Surgery.
PNI (comparison of
means).
Post-operative delirium. 30 days post-
surgery.
PNI associated with outcome. 7.0/10
Recruitment method not discussed.
Tei,
Japan [60]
≥75 YO
Median 79
Range 75–93
n= 311
F= 140
M= 171
Colorectal cancer.
Laparoscopic surgery.
PNI (comparison of
means).
Hb (10 g/dl).
Post-operative delirium. 30 days post-
surgery.
No association between proxy
markers and outcome.
8.0/10
Risk of selection bias and bias in
data collection.
Tominaga,
Japan [61]
≥70 YO n= 239
F= 118
M= 121
Colorectal cancer.
Curative resection.
PNI.
Body weight.
BMI.
Alb.
Hb (10–13/13–16/16–18/
<10/> 18 g/dl).
Post-operative complications
(Clavien-Dindo grade 2–5).
Median 25.7
months
(range
0.2–69.2).
PNI p ≤ 0.05 [no CI] and Alb p
= 0.04 [no CI] associated with
complications.
3.0/10
Risk of bias in data collection and
data presentation. Missing data.
Toya,
Japan [62]
≥75 YO
Median 78
Range 75–88
n= 87
F= 22
M= 65
Non-curative gastric cancer.
Endoscopic submucosal
dissection.
PNI </≥ 44.8.
GNRI ≤/> 92.
Overall survival. Median 6.7
years (range
0.1–14.8).
No association between proxy
markers and outcome.
8.0/10
Risk of selection bias and data
collection
Ueno,
Japan [63]
≥75 YO
Median
Range 75–91
n= 117
F= 35
M=82
Gastric cancer.
Curative surgery.
PNI </≥ 40. Overall survival.
Disease-specific survival.
Median 52.9
(range
1.0–117.5).
No association between proxy
marker and outcomes.
6.5/10
Risk of bias in data collection,
missing data.
Watanabe,
Japan [64]
≥75 YO
Median
Range
n= 99
F= 23
M= 76
Gastric cancer.
Curative intent gastrectomy.
PNI </≥44.7. Overall survival. 5 years. Proxy marker associated with
outcome.
9.0/10
Watanabe,
Japan [65]
≥75 YO
Median 79
Range 75–88
n= 131
F= 63
M= 68
Primary lung cancer.
Complete surgical resection.
PNI </≥ 45. Overall survival. 5 years. Proxy marker associated with
outcome.
9.0/10
Risk of selection bias
Yoshimatsu,
Japan [66]
≥80 YO
Median 83
Range 80–90
n= 76
F= 40
M= 36
Colorectal cancer.
Curative resection.
PNI </≥40. 3 and 5 year survival. Median 30
months.
No association between proxy
markers and outcomes.
2.0/10
Risk of bias data collection,
confounding, selection bias, data
presentation.
Zauderer,
USA [67]
≥70 YO Median
75
Range 70–92
n= 70
F= 20
M= 50
Metastatic non-small cell lung
cancer.
Chemotherapy.
Unintentional weight loss
(Y/N).
Alb </≥3.5 g/dl.
Anaemia (Y/N).
Chemotherapy complications;
grade 3/4 haematologic and
grade 4 non-haematologic
toxicity.
Treatment delay. Dose reduction.
Hospitalisation.
No info. No association between proxy
markers and outcomes.
1.5/10
Confounding not accounted for.
Convenience sample. Risk of bias
in data collection. Data
presentation.
R
elatio
n
sh
ip
b
etw
een
m
arkers
o
f
m
aln
u
tritio
n
an
d
clin
ical
o
u
tco
m
es
in
o
ld
er
ad
u
lts
w
ith
can
cer:...
Table 1 (continued)
Retrospective
cohort studies
Age, years Sample size,
gender
Cancer diagnoses and
treatment
Malnutrition proxy
markers
Patient outcomes Follow up Study results [95% CI] Quality score
Discontinuation of
chemotherapy due to toxicity.
Zhou,
China [68]
≥70 YO
Median 79
Range 75–91
n= 164
F= 67
M= 97
Oesophageal cancer.
Radiotherapy ± chemotherapy.
NRI </≥100. 2 year overall survival.
2 year local-regional failure-free
survival. 2 year distance
metastasis-free survival.
2 years. Proxy marker associated with
outcomes.
8.0/10
Risk of bias in data collection.
Missing data.
Cross-
sectional
studies
Age,
years
Sample size,
gender
Cancer diagnoses and treatment Malnutrition proxy
markers
Patient outcomes Follow
up
Study results [95% CI] Quality score
Girre,
France [69]
≥70 YO
Median
79
Range
70–97
n= 105
F= 87
M= 18
Breast, Lung, Colorectal, Cervix, Endometrial, Ovarian,
Prostate, Melanoma, Haematological. Other.
BMI (</≥ 23 kg/m2).
Hb (</≥ 12 g/dl).
Alb (20–35/>35 g/l).
Treatment plan
modification.
NA BMI associated with outcome,
p= 0.029 [no CI].
3.5/10
Risk of bias in data collection, selection
bias, Data presentation.
Rajasekaran,
Singapore
[70]
≥70 YO
Median
77
Range
70–94
n= 244
F= 95
M= 149
Gastrointestinal, Lung, Genitourinary, Other. BMI (</≥27.5 kg/m2).
Hb (</≥ 12 g/dl).
Dominant handgrip
(per kg increase).
Caregiver burden. NA Hb associated with outcome 7.5/10
Risk of confounding, study design.
Randomised
controlled trials
Age,
years
Sample size,
gender
Cancer diagnoses and
treatment
Malnutrition proxy
markers
Patient outcomes Follow up Study results [95% CI] Quality score
Aparicio,
France [71]
≥75 YO
Mean 80
± 3.7
n= 123
F= 57
M= 66
Metastatic colorectal cancer.
Chemotherapy.
BMI (≤20/20–30/ ≥30 kg/
m2
Hb (</≥ 10 g/dl females,
</≥ 11 g/dl males)
Dose intensity
reduction ≥33%.
Grade 3 to 4
toxicity.
≥1 Hospitalisation.
4 months after start
of treatment.
No association between proxy markers and
outcomes.
7.0/10
Risk of selection bias.
Falandry,
France [72]
≥70 YO
Median
79
Range
70–93
n= 98
F= 98
M= 0
Epithelial FIGO stage III or
IV ovarian cancer.
Chemotherapy.
Alb </≥ 35 g/l.
BMI </≥21 kg/m2
Overall survival. Median 17.4
months.
Alb associated with outcome in univariate
analysis; HR 2.36, [no CI] p=0.003.
4.5/10
Risk of confounding, risk of bias
in data collection.
n number, F female, M male, YO years old, OR odds ratios, HR hazard ratios, CI confidence intervals, NA not applicable Alb albumin, Hb haemoglobin, CRP C-reactive protein, BMI body mass
index NRI nutrition risk index, PNI prognostic nutritional index, GNRI geriatric nutrition risk index, CONUT controlling nutritional status score ADL activities of daily living.
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Prognostic nutritional index (PNI)
PNI was initially developed to assess Preoperative nutritional
status to predict post-operative complications in patients
undergoing gastrointestinal cancer surgery. PNI is calculated
using serum albumin concentration and the peripheral blood
lymphocyte count [7]. Cut-off points of <40 and <45 were
initially suggested to predict risk of surgical complications.
Thirteen studies investigated the relationship between PNI and
overall survival (OS) [43, 46, 50, 53–57, 62–66].
Meta-analysis Due to the heterogeneity in PNI thresholds
used, meta-analysis of only four studies, using receiver
operating characteristic curve estimates for OS was possi-
ble. A random-effects model was used to combine hazard
ratios (HRs) for OS and meta-analysis suggesting that lower
Preoperative PNI is associated with worse OS (HR 1.89
[95% CI 1.03–3.48, p= 0.04]), Fig. 2, I2= 65%.
Two studies investigated PNI and risk of POD [59, 60],
which demonstrated mixed results in multivariate analysis.
Both a statistically significant association (OR 1.257
[1.039–1.413] p= 0.003) [59] and no association (OR 1.016
[0.959–1.080] p= 0.475) [60] with POD was found [60].
Two studies investigated PNI to predict risk of post-
operative complications, although this only met statistical
significant in univariate analysis [58, 61].
Geriatric nutritional risk index (GNRI)
Two studies [48, 56] found an association between GNRI
and poorer patient outcomes. Low GNRI scores of <92
associated with post-operative complications Clavien-
Dindo grade ≥ 2 (HR 2.02 CI: 1.13–3.66]) [48], and
normal GNRI (≥98) associated with improved OS (HR
1.672 [CI: 1.079–2.581]) [56]. A third study [62] observed
no association between GNRI and OS (p= 0.91). Thresh-
olds for GNRI varied between 92 and 98.
Controlling nutritional status score (CONUT)
One study [56] reported an association between CONUT
and OS in multivariate analysis, but no relationship with
post-operative complications. A second smaller (n= 68)
study [57] found no association between CONUT and OS
or cancer-specific survival.
Nutritional risk index (NRI)
Two studies investigating NRI found low NRI was asso-
ciated with worse patient outcomes [36, 68]. One [68]
investigated NRI as a predictor of outcomes after anticancer
therapies in oesophageal cancer and found that NRI was
associated with poorer 2-year OS and distant metastasis-free
survival in multivariate analysis. The second [36] undertook
a smaller study (n= 71) and found low NRI to be asso-
ciated with post-operative complications in univariate ana-
lysis, but not with either major or infectious complications.
Anthropometric markers
Four anthropometric markers were identified in the reviewed
articles; BMI, weight loss, mid-arm circumference (MAC) and
calf circumference (CC), of which, 21 studies investigated BMI
[35, 37, 38, 40, 41, 44–48, 50, 53–57, 61, 69–72], eight weight
loss [33, 35, 36, 38, 45, 52, 61, 67] and one for MAC and CC
[35].
Table 2 Objective indexes.
PNI [7] PNI = 10 × albumin (g/dl)+ 0.005 × total lymphocyte count (per mm3)
CONUT
[84]
Serum Albumin (g/dl): ≥3.50 score 0, 3.00–3.49 score 2, 2.50–2.99 score 4, <2.50 score 6
Total lymphocyte count (mm3): ≥1600 score 0, 1200–1599 score 1, 800–1199 score 2,
<800 score 3
Total cholesterol (mg/dl): ≥180 score 0, 140–179 score 1, 100–139 score 2, <100 score 3
CONUT = serum albumin score + total lymphocyte score+ total cholesterol score
NRI [85] NRI = (1.519 × serum albumin (g/dl)) + (41.7 × current weight (kg)/ideal body weight (kg))
GNRI [86] GNRI = (1.489 × albumin (g/l)) + (41.7 × [weight/weight loss])
PNI prognostic nutritional index, CONUT controlling nutritional status score, NRI nutritional risk index,
GNRI geriatric nutritional risk index.
Fig. 1 Forest plot assessing the
correlation between declining
food intake and mortality.
Studies ordered by year (SE:
standard error, IV: inverse
variance, CI: confidence
interval).
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Body mass index (BMI)
Due to variable BMI thresholds and patient outcomes, meta-
analysis of results was not possible. Four studies
[44, 45, 47, 50] conducted multivariate analysis of BMI on
patient outcomes; with one [45] finding an association
between BMI < 18 kg/m2 and death within 3 months of
surgery. Another found BMI < 18 kg/m2 associated with
shorter survival [47]. Multivariate analysis also identified
associations with BMI and OS [50] and the clinical decision
of active versus palliative treatment [44].
In univariate analysis, associations were reported
between a BMI of 19–23 kg/m2 and patient outcomes; of
low BMI with mortality [35], treatment plan modification
[69], post-operative complications [56] and OS [46]. The
remaining 13 studies [37, 38, 40, 41, 48, 53–55, 57, 61, 70–
72] found no associations between BMI and patient out-
comes. BMI thresholds were heterogeneous and ranged
from 18 kg/m2 [47] to 30 kg/m2 [41].
Participants in the three studies [45, 47, 56] investigating
BMI < 18 kg/m2 on patient outcomes were all diagnosed
with NSCLC. These studies observed associations between
low BMI and poorer patient outcomes.
Weight loss
Only one study [45] conducted multivariate analysis of
weight loss on patient outcomes. A 5% weight loss in
3 months was associated with post-operative early death
within three months [45].
Three studies investigated the effect of weight loss on
mortality. Two studies [33, 35] found an association
between weight loss and mortality, where weight loss of
between 5 and 10%, >10%, >3 kg or unknown weight loss
were associated with 1-year mortality [35]. Weight loss in
the past 6 months was also associated with mortality [33].
The largest study, of 12,979 patients with colon cancer
reported no association between ‘weight loss’ and 90-day or
1-year mortality rates [52]. Three studies [36, 61, 67]
investigating weight loss and treatment complications found
no association.
Thresholds for weight loss varied from 5% [45], <5%,
5–10%, >10% [35], 1–3 kg, >3 kg [35], and unspecified
weight loss [52] in 3 month [45], 6 month [36] or unspe-
cified timeframes [67].
Mid arm circumference (MAC) and calf circumference (CC)
Only one study investigated MAC and CC in relation to
patient outcomes [73], finding CC < 31 cm and MAC <
21 cm to be associated with mortality in patients receiving
chemotherapy in univariate analysis.
Muscle strength
Two measures of muscle strength were identified in the
reviewed articles; hand-grip strength [39, 70] and lean
skeletal muscle-mass by CT [51]. A pilot study with 24
participants found no association between grip-strength and
chemotherapy toxicity [39]. Two studies reported associa-
tions between lean skeletal muscle mass with POD in
multivariate analysis [51], and grip-strength with caregiver
burden in univariate analysis [70].
Bio-markers
Three biomarkers were investigated; haemoglobin (Hb),
albumin (Alb) and CRP, of which 12 studies investigated
Hb [31, 32, 34, 37, 41, 49, 50, 60, 67, 69–71], 14 Alb
[31, 32, 34, 37, 38, 40, 41, 45, 46, 58, 61, 67, 69, 72] and 3
CRP [34, 38, 46].
Haemoglobin
Five studies [31, 32, 34, 49, 50] conducted multivariate
analysis of Hb on patient outcomes; with two studies
[34, 49] finding associations with Hb and OS, and a third
study reporting no association [50]. One small study (n=
44) [32] observed an association with Hb and mortality. No
relationship between Hb and chemotherapy toxicity or
complications were seen in three studies [37, 67, 71].
However, associations were seen between Hb and survival
[41], POD [60] and caregiver burden [70]. Thresholds for
Hb ranged between 100 [49] and 132 g/l [34] and the pre-
sence or absence of ‘anaemia’ [67].
Albumin
Four studies [31, 32, 34, 45] conducted multivariate ana-
lysis of albumin to predict patient outcomes; with only one
study [34] finding an association with OS, and one study
Fig. 2 Forest plot assessing the
correlation between PNI and
OS. Studies ordered by year.
(SE: standard error, IV: inverse
variance, CI: confidence
interval).
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with major post-operative complications [45]. No associa-
tion with mortality [31, 32], completion of chemotherapy
[31, 32] or death within 3 months of surgery were found
[45]. Univariate associations between Alb and post-
operative and chemotherapy-related complications were
seen in four studies [40, 58, 61, 67], and OS in two [41, 72].
There were no observed associations between Alb and OS
or disease-free survival [46], functional decline [38], or
chemotherapy toxicity [37] in three other studies. Thresh-
olds of Alb varied between 35 [31] and 40 g/l [40].
C-reactive protein
An association between increasing CRP and OS was seen in
one study [34] through multivariate analysis. There were no
observed relationships between CRP and OS [46] or func-
tional decline [38].
Discussion
Forty-two papers, representing 21,032 participants, inves-
tigating the associations of 15 makers of nutritional status
with patient outcomes, were identified for review. Our
meta-analysis of three questions regarding declining food
intake shows an association between reduced food intake
and mortality, but does not assess utilisation. Our meta-
analysis of four studies shows an association between
poorer PNI scores and clinical outcomes, but this score
measures inflammatory markers (which may indicate
increased energy requirement) but does not assess poor oral
intake. PNI alone, therefore cannot distinguish between
cachexia and malnutrition).
Measures of dietary intake and utilisation are essential in
diagnosing malnutrition, as these changes in consumption or
assimilation can lead to net calorific deficit and consequent
weight loss. Assessments of eating and drinking, despite being
a direct measure of intake, are inadequately, assessed in com-
monly used malnutrition screening tools (e.g. ESPEN criteria,
MUST). Several screening tools included an assessment of
appetite. Appetite may correlate with dietary intake in patients
with cancer, although it is only a proxy marker of malnutrition;
for example a patient with dysphagia due to localised oeso-
phageal cancer may be hungry but unable to eat. Food and
fluid intake arguably have the greatest face and content validity
for determining nutritional risk. From the available evidence,
there appears to be some evidence that reduced food and fluid
intake were associated with adverse patient outcomes in older
adults with cancer, with meta-analyses suggesting an associa-
tion between declining food intake with mortality, However,
there is an urgent need for more evidence, and in particular
studies which appropriately control for potential confounding
variables via multivariable analyses.
Whilst proxy markers of malnutrition can be easily used
and are commonly available, their value against direct
anthropometric markers or measures of food and fluid
intake is limited, see Table 3 for comparison of malnutrition
screening tool and objective indexes content, compared
with malnutrition markers identified in this review.
PNI was devised in 1984 as a risk score relating post-
operative complications with baseline nutrition, using
albumin and lymphocyte counts [7]. Our finding of an
association between low PNI and worse OS is consistent
with other recent meta-analyses of all adults with cancer
undergoing surgery [74–76]. Albumin and common
laboratory tests for inflammation (e.g. CRP and white cell
counts) are useful as predictors of prognosis in people with
cancer e.g. Glasgow Prognostic Score [77]. However, they
are not specific to malnutrition and are not recognised as a
diagnostic markers for malnutrition [78].
The single biomarkers identified in this review suggest
no clear association with patient outcomes. Although
reduced haemoglobin can be caused by dietary deficiency, it
may also be a feature of inflammation, chronic disease,
bone marrow suppression from anticancer treatments and
other wasting diseases (e.g. cachexia and sarcopenia
[79, 80]). Although the clinical presentation of malnutrition,
cachexia and sarcopenia overlap, Table 4, the management
of each differs [4, 19, 79, 80]. Therefore, the use of non-
specific biochemical and clinical markers, or objective
indices, which identify inflammation—albeit giving infor-
mation about increased metabolic and therefore nutritional
requirements—tell us nothing about dietary intake. There-
fore, in the absence of information about dietary intake,
they may reduce the specificity for malnutrition in an older
population at high risk of all three conditions.
Four anthropometric markers were examined in this
review: BMI, weight loss, MAC and CC. We found weight
loss was associated with worse clinical outcomes in older
adults with cancer. The varying thresholds in required
percentage weight loss and the timeframes for weight loss
used in the analysed literature, precluded meta-analysis or
identification of an appropriate threshold for weight loss to
indicate malnutrition in older adults with cancer. However,
weight loss does have face validity as a marker of mal-
nutrition. Weight loss is used in most malnutrition screening
tools [6].
As with weight loss, varying thresholds prohibited meta-
analysis of BMI. We found a low BMI (<18 kg/m2) predicts
poorer outcomes, particularly in lung cancer patients
[45, 47, 56]. MAC is known to correlate with BMI in
hospital inpatients [81]. BMI is a simple measure, easy to
implement in clinical practice but does not differentiate
between fat and muscle and repeat measures are needed to
be clinically useful. Adiposity mass increases with age and
muscle decreases without significant changes to BMI
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[82, 83], and the presence of sarcopenic obesity should be
considered.
Strengths and limitations
A strength of this study was the broad inclusion criteria of
patients with any cancer diagnosis, markers of nutritional
status and patient outcomes. This allowed a comprehensive
analysis of potential markers of nutritional status, and
appraisal of the evidence surrounding the validity of out-
comes in older adults with cancer. We chose to focus on
adults aged 70 years and over with cancer as this population
is both growing and complex; we address an important
clinical issue and identify a gap in clinical practice. This
patient group may present with multimorbidity and co-
existent cachexia and sarcopenia. Cancer patients are fre-
quently neglected from clinical trials and surgical and
pharmacological interventions require correction of nutri-
tional deficits before treatment commences.
There are a number of limitations. Firstly, due to the
heterogeneity in markers, marker thresholds, cancer diag-
noses, treatment types and study quality, meta-analysis of
most extracted data was not possible. Secondly, our aim
was to study malnutrition, therefore the search strategy was
not designed to capture all studies of general prognostic
markers in older adults with cancer. Few studies included
biomarkers. We acknowledge that some studies investigat-
ing Hb, Alb and CRP outside of a focus on malnutrition
may have been missed for this population. However, we are
unlikely to have missed any critical markers of malnutrition.
Finally, although lower weighting was given to lower
quality studies within results synthesis, due to the number
of lower quality studies, results may be treated with caution.
Implications for clinical practice and research
Measures of dietary intake should be sought as part of
routine nutritional assessment. The appropriateness of using
‘proxy’ markers of malnutrition should be reconsidered,
especially those overlapping with inflammation in older
adult patient groups with co-morbid conditions or acute
illness. Further research is required into the appropriate
thresholds for markers of nutritional status in this complex
population. A screening tool that can identify and
Table 3 Malnutrition screening
tools and objective indexes
compared with malnutrition
markers identified in review.
Biochemical Anthropometrics Dietary intake
Hb Alb CRP Weight loss BMI MAC/CC Hand-grip CT (LSMM) Food Fluid
BAPEN ● ● ● ●
CNST ● ●
CONUT ●
ESPEN ● ● ●a
GNRI ● ●
INSYST ● ●
MST ● ●
MSTC ● ● ●
MUST ● ● ●
NRI ● ●
NRS-2002 ● ● ●
NUFFE ● ● ●
PNI ●
SGA ● ●
SNAQ ● ●
3-MinNS ● ●
Alb albumin, BAPENBritish Association for Parenteral and Enteral Nutrition, BMI body mass index, CC calf
circumference, CNST Canadian Nutrition Screening Tool, CONUT controlling nutritional status, CT
computerised tomography, CRPC-reactive protein, ESPEN European Society for Clinical Nutrition and
Metabolism, GNRI geriatric nutritional risk index, Hb haemoglobin, INSYST imperial nutrition screening
system, LSMM lean skeletal muscle mass, MACmid-arm circumference, MSTmalnutrition screening tool,
NRS-2002 nutrition risk screening, MUSTmalnutrition universal screening tool, NRI nutrition risk index,
NUFFE nutritional form for the elderly, PNI prognostic nutritional index, SNAQ short nutritional assessment
questionnaire, SGA subjective global assessment, SNST simple nutrition screening tool, 3-MinNS 3 minute
nutrition screening.
aLow fat free mass index used instead of low skeletal muscle mass, defined as <15 kg/m2 in females and
<17 kg/m2 in males.
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Table 4 Diagnostic criteria and definitions for cachexia, sarcopenia and malnutrition.
Weight lo-
ss
B-
MI
Fatlos-
s
Fat
increa-
se
Loss of
muscle ma-
ss
Loss of muscle
strength/function
Low FF-
MI
Adverse
clinical
outcome
Diseasesta-
te
Age
rela-
ted
Catabolic/
inflam.
response
Abnormal
biomark
Anor-
exia
Insulin
resis-
tance
Fati-
gue
Oral inta-
ke
Cachexia
diagnoses
Evans et al. [79] ▲ □ ± □ □ ▲ ▲ □ ▲ □ ▲ □ ▲ ▲ □ □ ▲
Fearon et al. [19]
International Consensus
▲ ▲ ± □ ▲ □ □ □ □
Sarcopenia
diagnoses
Muscaritoli et al. [87] ▲ □ ▲ □
Fielding et al. [88] IWGS ± □ ▲ □ ▲ □ □a □ □a □a □a
Morley et al. [89] $
International Consensus
□ □
Cruz-Jentoft et al. [18] $
European Consensus
▲ □ ▲b □ □
Malnutri-
tion
diagnoses
NICE [90] § ▲ ▲
White et al. [78]c
(ASPEN & AND
Consensus)
▲ □ ▲ ▲ ▲ ± □ ▲□
Cederholm et al. [91]
(ESPEN Consensus) §
▲ ▲ ▲
Cederholm et al. [92]
GLIM Criteria §d
▲ ▲ ▲ ▲ ▲
Nutrition screening tools
[6]
▲ ▲ ▲ ▲ ▲ ▲ ▲ ▲ ▲ ▲ ▲ ▲
▲Diagnostic criteria.
□Definition ± with or without.
$Definition only.
§Diagnostic criteria only.
BMI body mass index, FFMI fat free muscle index, Inflam. inflammation, Biomark biomarker, NICENational Institute of Health and Care Excellence, APSENAmerican Society for Parenteral and
Enteral Nutrition, ANDAcademy of Nutrition and Dietetics, IWGS International Working Group for Sarcopenia.
aCauses of sarcopenia may include.
bPresence of low muscle quantity/quality and low physical performance indicates severe sarcopenia.
cDefinition adapted from Jensen et al. [93].
dPlus ‘at risk’ by one of: NRS-2002, MNA-SF, MUST, ESPEN, ASPEN/AND, SGA, Evans [79], Fougue [94], Fearon [19].
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differentiate between malnutrition, cachexia and sarcopenia
in older adults with cancer, and which is usable in clinical
practice, may allow targeted and appropriate treatment of
these conditions. Currently, there is none which can assess
all three conditions.
Conclusion
We could not identify a single tool suitable to screen for
malnutrition risk in older adults with cancer. Markers of
inflammation and measures or oral intake are used and are
associated with clinical outcomes. However, alone, they
cannot distinguish between risk of malnutrition, sarcopenia
and cachexia (which may co-exist in older adults with
cancer). Dietary intake measures in conjunction with others,
which measure nutritional utilisation, would be helpful. The
value, and best way, of differentiating between malnutri-
tion, cachexia and sarcopenia for older adults with cancer
remains unanswered.
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